antibody drug conjugate, resulted in significantly improved ORR lasting at least 4 months (56% vs 13%), median progression-free survival (PFS; 17 vs 4 months), and patient-reported symptom burden compared with methotrexate or bexarotene in patients with CD
Search Results
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
Featured Updates to the NCCN Guidelines
Neha Mehta-Shah, Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Kristopher Fisher, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Matthew A. Lunning, Amitkumar Mehta, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Satish Shanbhag, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar, and Youn H. Kim
Abstracts From the NCCN 23rdAnnual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
QLQ-C30, scored 0–100; higher scores indicate better QoL), symptom burden (Edmonton Symptom Assessment System), depression symptoms (Geriatric Depression Scale), number of independent activities of daily living (ADLs), and falls in the past year
Abstracts From the NCCN 2019 Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer CareTM
concerns (including depression and anxiety risk screening subscales), (2) symptom burden, (3) body and healthy lifestyle, (4) healthcare team communication, and (5) relationships. This study developed a short form of CSS and examined its psychometric
Palliative Care Version 1.2016
Michael Levy, Thomas Smith, Amy Alvarez-Perez, Anthony Back, Justin N. Baker, Anna C. Beck, Susan Block, Shalini Dalal, Maria Dans, Thomas R. Fitch, Jennifer Kapo, Jean S. Kutner, Elizabeth Kvale, Sumathi Misra, William Mitchell, Diane G. Portman, Todd M. Sauer, David Spiegel, Linda Sutton, Eytan Szmuilowicz, Robert M. Taylor, Jennifer Temel, Roma Tickoo, Susan G. Urba, Elizabeth Weinstein, Finly Zachariah, Mary Anne Bergman, and Jillian L. Scavone
) Curriculum . Princeton : The Robert Wood Johnson Foundation ; 1999 . 4. Cleeland CS Zhao F Chang VT . The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Jason Gotlib, Aaron T. Gerds, Prithviraj Bose, Mariana C. Castells, Michael W. Deininger, Ivana Gojo, Krishna Gundabolu, Gabriela Hobbs, Catriona Jamieson, Brandon McMahon, Sanjay R. Mohan, Vivian Oehler, Stephen Oh, Eric Padron, Philip Pancari, Nikolaos Papadantonakis, Animesh Pardanani, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Lindsay Rein, David S. Snyder, Brady L. Stein, Moshe Talpaz, Swapna Thota, Martha Wadleigh, Katherine Walsh, Mary Anne Bergman, and Hema Sundar
for patients with SSM), DEXA scan (every 1–3 years for patients with osteopenia or osteoporosis) and assessment of symptom burden and quality of life using MSAF and MQLQ is recommended for patients with ISM and SSM. Although increased serum beta-2
Cancer-Related Fatigue
Ann M. Berger, Amy Pickar Abernethy, Ashley Atkinson, Andrea M. Barsevick, William S. Breitbart, David Cella, Bernadine Cimprich, Charles Cleeland, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, Phyllis Kaldor, Jennifer A. Ligibel, Barbara A. Murphy, Tracey O'Connor, William F. Pirl, Eve Rodler, Hope S. Rugo, Jay Thomas, and Lynne I. Wagner
measured by a single item, or a subscale of an instrument designed to measure emotional distress, QOL, or general symptom burden. Furthermore, in many of these studies, fatigue was not an eligibility requirement, and in the studies that were directed
Cancer-Related Fatigue, Version 2.2015
Ann M. Berger, Kathi Mooney, Amy Alvarez-Perez, William S. Breitbart, Kristen M. Carpenter, David Cella, Charles Cleeland, Efrat Dotan, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, Catherine Jankowski, Thomas LeBlanc, Jennifer A. Ligibel, Elizabeth Trice Loggers, Belinda Mandrell, Barbara A. Murphy, Oxana Palesh, William F. Pirl, Steven C. Plaxe, Michelle B. Riba, Hope S. Rugo, Carolina Salvador, Lynne I. Wagner, Nina D. Wagner-Johnston, Finly J. Zachariah, Mary Anne Bergman, and Courtney Smith
secondary end point measured by a single item or a subscale of an instrument designed to measure emotional distress, QOL, or general symptom burden. Furthermore, fatigue was not an eligibility requirement. In studies specifically designed to measure fatigue
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Robert A. Swarm, Judith A. Paice, Doralina L. Anghelescu, Madhuri Are, Justine Yang Bruce, Sorin Buga, Marcin Chwistek, Charles Cleeland, David Craig, Ellin Gafford, Heather Greenlee, Eric Hansen, Arif H. Kamal, Mihir M. Kamdar, Susan LeGrand, Sean Mackey, M. Rachel McDowell, Natalie Moryl, Lisle M. Nabell, Suzanne Nesbit, BCPS, Nina O’Connor, Michael W. Rabow, Elizabeth Rickerson, Rebecca Shatsky, Jill Sindt, Susan G. Urba, Jeanie M. Youngwerth, Lydia J. Hammond, and Lisa A. Gurski
opioids. Opioid-related adverse effects were comparable across the 2 treatment groups, and overall well-being/symptom burden was rated as significantly better in the low-dose morphine arm. 58 Morphine, hydromorphone, hydrocodone, oxymorphone, and codeine
Abstracts From the NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
treatment modality on symptom burden and its effects on QOL. Methods: This cross-sectional observational study was conducted in a tertiary care teaching hospital in Punjab, India. A total of 125 heterogeneous patients with non-gastrointestinal cancer were
Abstracts From the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
. For the revised 25-item scale, 5 factors were suggested with eigenvalues >1.0: (1) emotional concerns (α=.91); (2) symptom burden and impact (α=.87); (3) body and healthy lifestyle concerns (α=.77); (4) relationship concerns (α=.68); and (5) healthcare
